Ruxolitinib + Allogeneic Stem Cell Transplantation in AML
This research study is studying a drug that may help decrease the chances of relapse after Allogeneic Stem Cell transplantation for Acute Myeloid Leukemia. The name of the study drug involved in this study is:
Phase II Study of Maintenance Ruxolitinib after Allogeneic Stem Cell Transplantation for Older Patients with Acute Myeloid Leukemia (AML) in First Complete Remission (CR1)
- ClinicalTrials.gov Identifier: NCT03286530
- Protocol Number: 17-273
- Principal Investigator: Myrna Nahas
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required